Taletrectinib in ROS1 Positive Lung Cancer Phase 2 Global Study
Status:
Not yet recruiting
Trial end date:
2027-06-01
Target enrollment:
Participant gender:
Summary
The main purpose of the study is to evaluate safety and efficacy of taletrectinib (also known
as AB-106 or DS-6051b) monotherapy in the treatment of advanced NSCLC.